Clovis M. Kumagai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Clovis M. Kumagai has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Ana Paula Frederico Rodrigues Loureiro Bracarense
Laboratory of Animal Pathology, Department of Preventive Veterinary Medicine, Universidade Estadual de Londrina, Londrina, Brazil
1 shared publication - Barbara B. Colombo
Departamento de Ciências Patológicas, Universidade Estadual de Londrina, Rodovia Celso Garcia Cid, Km 80, PR445, Cx. Postal 10.011, 86057-970 Londrina, Brazil
1 shared publication - Camilla C. A. Rodrigues
Department of Pharmaceutical Sciences, Centre of Health Science, Londrina State University, Avenida Robert Koch, 60, Londrina 86038-350, PR, Brazil
1 shared publication - David L. Vale
Department of Pharmaceutical Sciences, Centre of Health Science, Londrina State University, Avenida Robert Koch, 60, Londrina 86038-350, PR, Brazil
1 shared publication - Ingrid C. Pinto
Department of Pharmaceutical Sciences, Health Sciences Center, Londrina State University, Londrina CEP 86039-440, Brazil
1 shared publication - Juliana Trindade Clemente-Napimoga
Faculdade São Leopoldo Mandic
1 shared publication
Latest Publications
- Open Access
- 1 January 2021
- Published by Wiley in Mediators of Inflammation
- Vol. 2021 (1)
Topical Administration of 15‐Deoxy‐Δ12,14‐Prostaglandin J2 Using a Nonionic Cream: Effect on UVB‐Induced Skin Oxidative, Inflammatory, and Histopathological Modifications in Mice
UVB radiation is certainly one of the most important environmental threats to which we are subjected to. This fact highlights the crucial protective role of the skin. However, the skin itself may not be capable of protecting against UVB depending on irradiation intensity and time of exposition. Sun blockers are used to protect our skin, but they fail to fully protect it against oxidative and inflammatory injuries initiated by UVB. To solve this issue, topical administration of active molecules is an option. 15‐Deoxy‐Δ12,14‐prostaglandin J2 (15d‐PGJ2) is an arachidonic acid‐derived lipid with proresolution and anti‐inflammatory actions. However, as far as we are aware, there is no evidence of its therapeutic use in a topical formulation to treat the deleterious events initiated by UVB, which was the aim of the present study. We used a nonionic cream to vehiculate 15d‐PGJ2 (30, 90, and 300 ng/mouse) (TFcPGJ2) in the skin of hairless mice. UVB increased skin edema, myeloperoxidase activity, metalloproteinase‐9 activity, lipid peroxidation, superoxide anion production, gp91phox and COX‐2 mRNA expression, cytokine production, sunburn and mast cells, thickening of the epidermis, and collagen degradation. UVB also diminished skin ability to reduce iron and scavenge free radicals, reduced glutathione (GSH), sulfhydryl proteins, and catalase activity. TFcPGJ2 inhibited all these pathological alterations in the skin caused by UVB. No activity was observed with the unloaded topical formulation. The protective outcome of TFcPGJ2 indicates it is a promising therapeutic approach against cutaneous inflammatory and oxidative pathological alterations.
- 1 January 2021
- Published by Wiley in Mediators of Inflammation
- Vol. 2021 (1)
Open AccessTopical Administration of 15‐Deoxy‐Δ12,14‐Prostaglandin J2 Using a Nonionic Cream: Effect on UVB‐Induced Skin Oxidative, Inflammatory, and Histopathological Modifications in Mice
UVB radiation is certainly one of the most important environmental threats to which we are subjected to. This fact highlights the crucial protective role of the skin. However, the skin itself may not be capable of protecting against UVB depending on irradiation intensity and time of exposition. Sun blockers are used to protect our skin, but they fail to fully protect it against oxidative and inflammatory injuries initiated by UVB. To solve this issue, topical administration of active molecules is an option. 15‐Deoxy‐Δ12,14‐prostaglandin J2 (15d‐PGJ2) is an arachidonic acid‐derived lipid with proresolution and anti‐inflammatory actions. However, as far as we are aware, there is no evidence of its therapeutic use in a topical formulation to treat the deleterious events initiated by UVB, which was the aim of the present study. We used a nonionic cream to vehiculate 15d‐PGJ2 (30, 90, and 300 ng/mouse) (TFcPGJ2) in the skin of hairless mice. UVB increased skin edema, myeloperoxidase activity, metalloproteinase‐9 activity, lipid peroxidation, superoxide anion production, gp91phox and COX‐2 mRNA expression, cytokine production, sunburn and mast cells, thickening of the epidermis, and collagen degradation. UVB also diminished skin ability to reduce iron and scavenge free radicals, reduced glutathione (GSH), sulfhydryl proteins, and catalase activity. TFcPGJ2 inhibited all these pathological alterations in the skin caused by UVB. No activity was observed with the unloaded topical formulation. The protective outcome of TFcPGJ2 indicates it is a promising therapeutic approach against cutaneous inflammatory and oxidative pathological alterations.